Pancreatic cancer and fibrosis: Targeting metabolic reprogramming and crosstalk of cancer-associated fibroblasts in the tumor microenvironment

Frontiers in Immunology

Immunology

Fu Peng¹  Chunxi Li¹  Qiaoling Wan¹  Jianbo Zhou¹  Zifan Ma¹  Xue Wang¹  Xin Li¹ 

[1] Department of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China;

关键词: pancreatic cancer;    cancer-associated fibroblasts;    fibrosis;    metabolic reprogramming;    crosstalk;    heterogeneity;   

DOI  :  10.3389/fimmu.2023.1152312

 received in 2023-01-27, accepted in 2023-03-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

Pancreatic cancer is one of the most dangerous types of cancer today, notable for its low survival rate and fibrosis. Deciphering the cellular composition and intercellular interactions in the tumor microenvironment (TME) is a necessary prerequisite to combat pancreatic cancer with precision. Cancer-associated fibroblasts (CAFs), as major producers of extracellular matrix (ECM), play a key role in tumor progression. CAFs display significant heterogeneity and perform different roles in tumor progression. Tumor cells turn CAFs into their slaves by inducing their metabolic dysregulation, exacerbating fibrosis to acquire drug resistance and immune evasion. This article reviews the impact of metabolic reprogramming, effect of obesity and cellular crosstalk of CAFs and tumor cells on fibrosis and describes relevant therapies targeting the metabolic reprogramming.

【 授权许可】

Unknown   
Copyright © 2023 Li, Zhou, Wang, Li, Ma, Wan and Peng